To determine frequency of Anti-TPO antibodies in vitiligo patients

Rabia Anjum, Faria Altaf, Dr. Raffad, Zahida Rani, Nabeela Shahzadi, Wajieha Saeed


Background Vitiligo is an acquired depigmenting disorder due to destruction of melanocytes. An increased prevalence of autoimmune thyroid disease has been described in these patients.


Objective To determine frequency of Anti-TPO antibodies in vitiligo patients.


Materials and Methods  A cross-sectional survey conducted at 3 different hospitals for 6months. 77 patients were enrolled. All the variables were recorded in proforma. Blood samples were collected under aseptic conditions and were sent to one laboratory for thyroid function tests and anti-TPO antibody test by ELISA.


Results In this study abnormal TFTs were seen in 7(9.1%) patients. Among these patients 2(28.6%) were diagnosed as hyperthyroid and 5(71.4%) were diagnosed as hypothyroid. Anti-TPO antibodies were positive in 11(14.3%) patients only. Frequency of Anti-TPO antibodies were significantly higher in younger patients i.e. 16-30 years (63.3%).


Conclusion Results of this study showed low frequency of Anti-TPO antibodies positivity in vitiligo patients. A significant association was seen between Anti-TPO antibodies with age and hypothyroidism. Patients with anti-TPO antibodies should be followed-up annually, because thyroid dysfunction can develop much later. Both vitiligo and thyroid disorders are fairly common in our population, and early screening and diagnosis help to reduce the morbidity associated with thyroid dysfunction.



Anti-TPO, Antibodies, Vitiligo, Hypothyroidism, hyperthyroidism

Full Text:



Felsten LM, AliKhan A, Petronicrosic V. Vitiligo: a comprehensive overview. J Am Acad Dermatol 2011; 65: 493-514.

Afsar FS, Isleten F. Prevalence of thyroid function test abnormalities and thyroid autoantibodies in children with vitiligo. Indian J endocrinol metabol 2013; 17: 1096-1099.

Kasumagic HE, Ovcina KN, Jukic T, Karamehic J, Begovic B, Samardzic S. Vitiligo and autoimmunity. Med Arch 2013; 67: 91-3.

Vrijman C, Kroon MW, Limpens J, Leeflang MM, Luiten RM, Van der veen JP, Wolkerstorfer A, Spuls PL. The prevalence of thyroid disease in patients with vitiligo: a systemic review. Br J Dermatol 2012; 167: 1224-35.

Kroon MW, Vrijman C, Chandeck C, Wind BS, Wolkerstorfer A, Luiten RM, Bos JD, Geskus RB, Van Trostenburg P, Van der Veen JP. High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr 2013; 79: 137-44.

Gey A, Diallo A, Seneschal J. Leaute-Labreze C, Boralevi F, Jouary T, Taieb A, Ezzedine K. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms. Br J Dermatol 2013; 168: 756-61.

Yang Y, Huang G, Yan X, Qing Z. Clinical analysis of thyroglobulin antibody and thyroid peroxidase antibody and their association with vitiligo. Indian J Dermatol 2014; 59: 357-360.

Kemp EH. Antithyroid hormone autoantibodies in vitiligo. Br J Dermatol 2014; 171: 690.

Hinah A, Hassan IS, Maqsood QA. Evaluation of thyroid function and presence of anti-thyroid peroxidase antibodies in patients with vitiligo. Egyptian Dermatol online J 2010; 6: 3.

Ammini A, Gupta Y. Vitiligo, hypothyroidism and cardiomyopathy. Indian J Endocrinol Metabol 2012; 16(3): 463.

Laberge G, Mailloux C, Gowan K, Holland P, Bennett D, Fain P et al. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res 2005; 18(4): 300-305.

Ai J, Leonhardt JM, Heymann WR. Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations. JAAD 2003; 48(5): 641-62.

Saravanan P, Dayan C. THYROID AUTOANTIBODIES. Endocrinol Metabol Clin North Am. 2001; 30(2): 315-337.

Chardès T, Chapal N, Bresson D, Bès C, Giudicelli V, Lefranc M et al. The human anti-thyroid peroxidase autoantibody repertoire in Graves' and Hashimoto's autoimmune thyroid diseases. Immunogenetics 2002; 54(3): 141-157.

McLachlan SM, Rapoport B. Autoimmune response to the thyroid in humans: thyroid peroxidase-the common autoantigenic denominator. Int Rev Immunol 2000; 19(6): 587-618.

Trbojević B, Đurica S. Diagnosis of autoimmune thyroid disease. Srp Arh Celok Lek 2005; 133(1): 25-33.

Melmed, Shlomo. Williams Textbook of Endocrinology (12th ed.). Philadelphia: Elsevier/Saunders. p. 355.

Daneshpazhooh M, Behjati J, Akhyani M, Robati RM. Anti-thyroid peroxidase antibody and vitiligo: a controlled study. BMC dermatol 2006; 6(1):3.

Moradi S, Ghaffarpour GH. Thyroid Dysfunction and Thyroid Anti-Bodies in Iranian Patients with Vitiligo. RJMS 2008; 15(58): 163-8.

Jishna P, Binitha M, Anilakumari V. Prevalence of thyroid dysfunction and anti-thyroid peroxidase antibodies in vitiligo patients. Int J Res Dermatol 2017; 3(1): 140-4.

Dash R, Mohapatra A, Manjunathswamy B. Anti-thyroid peroxidase antibody in vitiligo: a prevalence study. J Thyroid Res 2015; 2015.

Nunes DH, Esser LMH. Vitiligo epidemiological profile and the association with thyroid disease. An Bras Dermatol 2011; 86(2): 241-8.

Kumar K, Priya S, Sharma R, Kapoor U, Saini M, Bisht Y. Autoimmune thyroid isease in patients with vitiligo: prevalence study in India. Endocrinol Pract 2011; 18(2): 194-9.

Dogra S, Parsad D, Handa S, Kanwar AJ. Late onset vitiligo: a study of 182 patients. Int J Dermatol 2005; 44(3): 193-6.

Al-Mutairi N, Sharma AK. Profile of vitiligo in Farwaniya region in Kuwait. Kuwait Med J 2006; 38(2): 128.


  • There are currently no refbacks.

ISSN: 1560-9014